Optic Neuritis Clinical Trials

Find Optic Neuritis Clinical Trials Near You

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain. This trial compares the effectiveness and safety of five medications commonly used to prevent NMOSD relapses: rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab. In this study, 160 adults with NMOSD who test positive for a specific antibody (AQP4-IgG) will participate. They will be randomly assigned to receive either rituximab or one of the four other FDA-approved medications. The main goal is to find out which treatment best prevents relapses and has fewer serious side effects. The trial will also measure disability, patient satisfaction, quality of life, and biomarkers that help track disease activity. Participants will have regular assessments, including medical exams, surveys, and tests for vision, walking ability, and brain function. They will report any side effects or health issues experienced during the study. The trial will last from one to four years for each participant. This research aims to help patients and doctors make better-informed treatment decisions by providing clear evidence about the best available therapies for NMOSD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Diagnosis of NMOSD according to the 2015 International Panel for NMO Diagnosis (IPND) consensus criteria.

• Seropositivity for AQP4 immunoglobulin G (AQP4-IgG) confirmed by a cell-based assay (either live or fixed) that meets the threshold for positivity set by the local testing laboratory.

• Age ≥18 years at the time of consent.

• Ability and willingness to provide informed consent and comply with all study procedures, including scheduled visits, laboratory tests, and assessments.

• Eligible to receive any of the study drugs based on clinical judgment

Locations
United States
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
Massachusetts General Hospital
RECRUITING
Boston
Other Locations
Germany
Charité - Universitätsmedizin Berlin
NOT_YET_RECRUITING
Berlin
Contact Information
Primary
Philippe-Antoine Bilodeau, MD
pbilodeau@mgh.harvard.edu
617-726-7565
Backup
Anastasia Vishnevetsky, MD
avishnevetsky@mgb.org
617-726-7565
Time Frame
Start Date: 2026-09-01
Estimated Completion Date: 2030-05
Participants
Target number of participants: 540
Treatments
Active_comparator: Rituximab
Experimental: Complement inhibitors
Ravulizumab or eculizumab
Experimental: Inebilizumab
Experimental: Satralizumab
Other: Open-label, non-randomized
Open-label, non-randomized
Sponsors
Leads: Massachusetts General Hospital
Collaborators: Charite University, Berlin, Germany, The Sumaira Foundation, Patient-Centered Outcomes Research Institute

This content was sourced from clinicaltrials.gov